Overhauling the Models That Reach Patients

A theme kept surfacing as I read through the articles in this issue. Across distribution, access, pricing and patient support, the same problem keeps showing up in different forms: the models the industry inherited were built for conditions that have since changed.

You can see it in distribution, where a system designed to move full pallets through wholesalers now has to handle N-of-one cell and gene therapies and mass-market GLP-1s at the same time; that’s two opposite problems that land on the cold chain, one demanding cryogenic, single-patient custody and the other demanding temperature control at consumer scale. You can see it in commercialization, where the assumption that every successful product should run through commercial insurance is being challenged by a market that has fragmented into three payer economies. You can see it in the hub, where transitions that look like vendor swaps are really operating-model corrections. And you can see it in lifecycle change management, a discipline that quietly governs every marketed product yet still runs on spreadsheets and status calls that have not changed in two decades.

What makes this issue worth your time is that none of these articles stops at diagnosis. They get specific about what comes next: real-time visibility that turns cold chain packaging from a passive layer into a managed system; real-world evidence strategies designed to be used by payers, not just produced for them; minimum viable launches that protect speed to therapy instead of chasing feature lists; and automation in pharmacovigilance and access that earns its place rather than replacing the human judgment these decisions still require.

That last point runs through nearly everything here. AI is in almost every article in this issue, but the most useful voices are not the loudest ones. They treat it as augmentation, insist on governance and remember that trust is easy to compress and hard to rebuild.

My job, as I see it, is to keep this publication asking the harder question underneath all of this: not whether the old models are breaking, but what the industry is building to replace them, and whether it works for patients.

As always, I would love to hear from you. If there is a model in your corner of the business that no longer fits the market it was built for, that is a story worth telling.